<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department - Kew, KM - 2014 | Cochrane Library</title> <meta content="Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department - Kew, KM - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010909.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department - Kew, KM - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010909.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010909.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department" name="citation_title"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="kkew@sgul.ac.uk" name="citation_author_email"/> <meta content="Liza Kirtchuk" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Clare I Michell" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD010909.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010909.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010909.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010909.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Emergency Service, Hospital; Anti‐Asthmatic Agents [*administration &amp; dosage, adverse effects]; Asthma [*drug therapy]; Hospitalization [statistics &amp; numerical data]; Infusions, Intravenous [methods]; Magnesium Sulfate [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010909.pub2&amp;doi=10.1002/14651858.CD010909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010909\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010909\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010909.pub2",title:"Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department",firstPublishedDate:"May 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010909.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010909.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010909.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010909.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010909.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010909.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010909.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010909.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010909.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010909.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>35317 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010909.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0113"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-sec-0107"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/appendices#CD010909-sec-0118"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/table_n/CD010909StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/table_n/CD010909StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#CD010909-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#CD010909-cr-0003">Liza Kirtchuk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information#CD010909-cr-0004">Clare I Michell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information/en#CD010909-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010909.pub2">https://doi.org/10.1002/14651858.CD010909.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010909-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010909-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010909-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010909-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010909-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010909-abs-0001" lang="en"> <section id="CD010909-sec-0001"> <h3 class="title" id="CD010909-sec-0001">Background</h3> <p>Asthma is a chronic respiratory condition characterised by airways inflammation, constriction of airway smooth muscle and structural alteration of the airways that is at least partially reversible. Exacerbations of asthma can be life threatening and place a significant burden on healthcare services. Various guidelines have been published to inform management personnel in the acute setting; several include the use of a single bolus of intravenous magnesium sulfate (IV MgSO<sub>4</sub>) in cases that do not respond to first‐line treatment. However, the effectiveness of this approach remains unclear, particularly in less severe cases. </p> </section> <section id="CD010909-sec-0002"> <h3 class="title" id="CD010909-sec-0002">Objectives</h3> <p>To assess the safety and efficacy of IV MgSO<sub>4</sub> in adults treated for acute asthma in the emergency department. </p> </section> <section id="CD010909-sec-0003"> <h3 class="title" id="CD010909-sec-0003">Search methods</h3> <p>We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR) up to 2 May 2014. We also searched www.ClinicalTrials.gov and reference lists of other reviews, and we contacted trial authors to ask for additional information. </p> </section> <section id="CD010909-sec-0004"> <h3 class="title" id="CD010909-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of adults treated in the emergency department (ED) for exacerbations of asthma if they compared any dose of IV MgSO<sub>4</sub> with placebo. </p> </section> <section id="CD010909-sec-0005"> <h3 class="title" id="CD010909-sec-0005">Data collection and analysis</h3> <p>All review authors screened titles and abstracts for inclusion, and at least two review authors independently extracted study characteristics, risk of bias and numerical data. Disagreements were resolved by consensus, and we contacted trial investigators to obtain missing information. </p> <p>We analysed dichotomous data as odds ratios using study participants as the unit of analysis, and we analysed continuous data as mean differences or standardised mean differences using fixed‐effect models. We rated all outcomes using GRADE and presented results in Summary of findings table 1. </p> <p>We carried out subgroup analyses on the primary outcome for baseline severity of exacerbations and whether or not ipratropium bromide was given as a co‐medication. Unpublished data and studies at high risk of bias for blinding were removed from the main analysis in sensitivity analyses. </p> </section> <section id="CD010909-sec-0006"> <h3 class="title" id="CD010909-sec-0006">Main results</h3> <p>Fourteen studies met the inclusion criteria, randomly assigning 2313 people with acute asthma to the comparisons of interest in this review. </p> <p>Most studies were double‐blinded trials comparing a single infusion of 1.2 g or 2 g IV MgSO<sub>4</sub> over 15 to 30 minutes versus a matching placebo. Eleven were conducted at a single centre, and three were multi‐centre trials. Participants in almost all of the studies had already been given at least oxygen, nebulised short‐acting beta<sub>2</sub>‐agonists and IV corticosteroids in the ED; in some studies, investigators also administered ipratropium bromide. Ten studies included only adults, and four included both adults and children; these were included because the mean age of participants was over 18 years. </p> <p>Intravenous MgSO<sub>4</sub> reduced hospital admissions compared with placebo (odds ratio (OR) 0.75, 95% confidence interval (CI) 0.60 to 0.92; I<sup>2</sup> = 28%, P value 0.18; n = 972; high‐quality evidence). In absolute terms, this odds ratio translates into a reduction of seven hospital admissions for every 100 adults treated with IV MgSO<sub>4</sub> (95% CI two to 13 fewer). The test for subgroup differences revealed no statistical heterogeneity between the three severity subgroups (I<sup>2</sup> = 0%, P value 0.73) or between the four studies that administered nebulised ipratropium bromide as a co‐medication and those that did not (I<sup>2</sup> = 0%, P value 0.82). Sensitivity analyses in which unpublished data and studies at high risk for blinding were removed from the primary analysis did not change conclusions. </p> <p>Within the secondary outcomes, high‐ and moderate‐quality evidence across three spirometric indices suggests some improvement in lung function with IV MgSO<sub>4</sub>. No difference was found between IV MgSO<sub>4</sub>and placebo for most of the non‐spirometric secondary outcomes, all of which were rated as low or moderate quality (intensive care admissions, ED treatment duration, length of hospital stay, readmission, respiration rate, systolic blood pressure). </p> <p>Adverse events were inconsistently reported and were not meta‐analysed. The most commonly cited adverse events in the IV MgSO<sub>4</sub> groups were flushing, fatigue, nausea and headache and hypotension (low blood pressure). </p> </section> <section id="CD010909-sec-0007"> <h3 class="title" id="CD010909-sec-0007">Authors' conclusions</h3> <p>This review provides evidence that a single infusion of 1.2 g or 2 g IV MgSO<sub>4</sub> over 15 to 30 minutes reduces hospital admissions and improves lung function in adults with acute asthma who have not responded sufficiently to oxygen, nebulised short‐acting beta<sub>2</sub>‐agonists and IV corticosteroids. Differences in the ways the trials were conducted made it difficult for the review authors to assess whether severity of the exacerbation or additional co‐medications altered the treatment effect of IV MgSO<sub>4</sub>. Limited evidence was found for other measures of benefit and safety. </p> <p>Studies conducted in these populations should clearly define baseline severity parameters and systematically record adverse events. Studies recruiting participants with exacerbations of varying severity should consider subgrouping results on the basis of accepted severity classifications. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010909-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010909-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010909-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010909-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010909-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010909-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010909-abs-0010">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010909-abs-0004" lang="en"> <h3>Do magnesium sulfate infusions reduce the need for hospital admission in adults with acute asthma? </h3> <p><b>Why is this question important?</b> <br/> Asthma is a long‐term condition that causes coughing, wheezing, shortness of breath and chest tightness. When symptoms significantly worsen, often referred to as an attack or 'exacerbation,' this can be life threatening. Management of exacerbations in the emergency department (ED) varies, and some guidelines recommend the use of intravenous magnesium sulfate (IV MgSO<sub>4</sub>) when other treatments have not helped. However, it is unclear whether IV MgSO<sub>4</sub> is effective, particularly in less severe cases, and we wanted to answer this question. </p> <p><b>How did we answer the question?</b> <br/> We looked for trials that compared IV MgSO<sub>4</sub> versus placebo in adults attending the ED with an asthma exacerbation. The most recent searches were done on 2 May 2014. We were interested primarily in whether IV MgSO<sub>4</sub> reduced the number of people needing to be admitted to hospital, and we looked at several other measures as well, including time spent in the ED, lung function and symptom scores. </p> <p><b>What did we find?</b> <br/> Fourteen studies met the inclusion criteria, involving a total of 2313 people. These studies varied in terms of how bad exacerbations had to be for people to be included and in terms of what other treatments were provided before IV MgSO<sub>4</sub>was given, but almost all trials gave participants at least oxygen, nebulised short‐acting medications and steroid tablets or injection. </p> <p>Overall, IV MgSO<sub>4</sub> reduced the need for hospital admission compared with placebo (seven fewer per 100 treated; 95% confidence interval two to 13 fewer). Not enough information was available to show whether the reduction in hospital admissions was associated with severity of the asthma exacerbation, or whether it made a difference what other treatments were given. Evidence suggests that IV MgSO<sub>4</sub> improved some lung function parameters, but for other measures such as heart rate, variation among study findings reduced our confidence in the results. We did not find a difference between IV MgSO<sub>4</sub> and placebo in most other measures (including time spent in the ED, respiratory rate and blood pressure), and adverse events generally were poorly reported. </p> <p><b>Conclusion</b> <br/> This review showed that IV MgSO<sub>4</sub> reduces hospital admissions and improves lung function in adults with exacerbations of asthma when other first‐line medications have not relieved the acute symptoms (i.e. oxygen, inhaled short‐acting medications and IV steroids). Evidence for other measures of benefit and safety was limited. </p> <p>Researchers should clearly define the severity of the asthma condition among people in their studies while carefully recording adverse events. </p> <p>This plain language summary is current as of May 2014.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010909-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010909-sec-0113"></div> <h3 class="title" id="CD010909-sec-0114">Implications for practice</h3> <section id="CD010909-sec-0114"> <p>This review provides evidence that a single infusion of 1.2 g or 2 g IV MgSO<sub>4</sub> over 15 to 30 minutes reduces hospital admissions and improves lung function in adults with acute asthma who have not responded sufficiently to oxygen, nebulised short‐acting beta<sub>2</sub>‐agonists and IV corticosteroids. Differences in the ways the trials were conducted made it difficult to assess whether the severity of the exacerbation, or additional co‐medications, altered the treatment effect of IV MgSO<sub>4</sub>. Evidence for other measures of benefit and safety was limited. </p> </section> <h3 class="title" id="CD010909-sec-0115">Implications for research</h3> <section id="CD010909-sec-0115"> <p>Studies conducted in these populations should clearly define baseline severity parameters and systematically record adverse events. Studies recruiting participants with exacerbations of varying severity should consider subgrouping results on the basis of accepted severity classifications. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010909-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010909-sec-0029"></div> <div class="table" id="CD010909-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IV MgSO4 for treating adults with acute asthma in the emergency department</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>IV MgSO<sub>4</sub> for treating adults with acute asthma in the ED</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with acute asthma<br/> <b>Settings:</b> emergency department<br/> <b>Intervention:</b> IV MgSO<sub>4</sub> </p> <p><b>Comparions:</b> placebo </p> <p>Both intervention and placebo groups received oxygen, short‐acting beta<sub>2</sub>‐agonists and oral or intravenous steroids before the infusion. </p> <p>Measurements were taken between 60 and 240 minutes after the start of the infusion.</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IV MgSO<sub>4</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> <br/> (442 to 549) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.75</b> <br/> (0.60 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1769<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) admissions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.03</b> <br/> (0.7 to 5.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>752<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay in the control groups was<br/> <b>2.73 days</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay in the intervention groups was<br/> <b>0.03 days lower</b> <br/> (0.33 lower to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>949<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ED treatment duration (minutes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean duration in the placebo group was</p> <p><b>228 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ED treatment duration in the intervention groups was<br/> <b>4 minutes lower</b> <br/> (37.02 lower to 29.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>9,10,11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> in the placebo group was </p> <p><b>50% predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> (% predicted) in the intervention groups was<br/> <b>4.41 higher</b> <br/> (1.75 to 7.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>523<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>12,13,14</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEF (L/min)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean PEF in the placebo group was</p> <p><b>239 L/min</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean PEF in the intervention groups was<br/> <b>17.4 L/min higher</b> <br/> (8.64 to 26.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1460<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>15,16,17</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory rate (breaths/min)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean respiration rate in the placebo group was</p> <p><b>20.7 respirations/min</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean respiratory rate in the intervention groups was<br/> <b>0.28 breaths/min lower</b> <br/> (0.77 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1195<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>18,19,20</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>ED</b> : Emergency department; <b>FEV<sub>1</sub> </b> : Forced expiratory volume in 1 second; <b>ICU</b>: Intensive care unit; IV: Intravenous; MgSO<sub>4</sub>: Magnesium sulfate; <b>OR</b> : Odds ratio; <b>PEF</b>: Peak expiratory flow. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>One study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>) introduced risk of bias, but the rest of the studies were generally well conducted.<br/> <sup>2</sup>I<sup>2</sup> = 28%; P value 0.18; not statistically significant.<br/> <sup>3</sup>Confidence interval includes potential benefit and harm. Very few events and only 1 study (‐2 for imprecision).<br/> <sup>4</sup>Only 1 study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>) reported this outcome, but no other studies set out to measure it at the outset.<br/> <sup>5</sup>Weighted by sample size.<br/> <sup>6</sup>Two of the 3 studies were at high risk of bias for blinding, and there were some issues with selection bias.<br/> <sup>7</sup>I<sup>2</sup> = 58%; P value 0.07, suggesting statistically significant heterogeneity.<br/> <sup>8</sup>Although only 3 studies reported this outcome, it was not named as an outcome in other studies.<br/> <sup>9</sup>Only 1 study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>), which was assessed as having high risk of bias for several domains.<br/> <sup>10</sup>Only 1 study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>), which had wide confidence intervals (‐37.02 to 29.02).<br/> <sup>11</sup>Only 1 study reported ED treatment duration, but it was not named as an outcome in other studies.<br/> <sup>12</sup>Only 1 study (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>) had the potential for risk of bias, but all other studies were low risk and included large numbers of participants.<br/> <sup>13</sup>No significant heterogeneity was noted (I<sup>2</sup> = 14%; P value 0.33).<br/> <sup>14</sup>Moderately wide confidence interval (1.75 to 7.06), but after discussion, review authors decided that no downgrade was required.<br/> <sup>15</sup>Two studies (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>) had 'unclear' and 'high' risk of bias, respectively. However, the remaining 6 studies were of low risk and contributed most of the participant numbers.<br/> <sup>16</sup>Some heterogeneity between the studies, which was statistically significant (I² = 50%; P value 0.05). However, when random effects were applied, conclusions were not changed.<br/> <sup>17</sup>Wide confidence intervals (8.64 to 26.17), but does not cross zero.<br/> <sup>18</sup>Very little heterogeneity observed between the studies (I² = 1%), which was not significant (P value 0.39).<br/> <sup>19</sup>Confidence interval (‐0.77 to 0.20) includes significant benefit and potential harm (i.e. crosses the line of no effect).<br/> <sup>20</sup>Only 4 studies reported respiratory rate, but it was not named as an outcome in other studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010909-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010909-sec-0030"></div> <section id="CD010909-sec-0031"> <h3 class="title" id="CD010909-sec-0031">Description of the condition</h3> <p>Asthma is a chronic respiratory condition characterised by airway inflammation, constriction of airway smooth muscle and structural alteration of the airways that is at least partially reversible. Common symptoms include cough, wheezing, difficulty breathing, reduced exercise tolerance and chest tightness. Common triggers include allergens, pollutants and viral infections, although endogenous factors have also been identified. The World Health Organization (WHO) recognises the global burden of asthma and estimates a worldwide prevalence of 300 million people of all ages, with 250,000 dying each year. Epidemiological data suggest that prevalence is greatest in the developed world, with prevalence amongst adults at 8.2% in the USA (<a href="./references#CD010909-bbs2-0030" title="Centers for Disease Control and Prevention. Asthma Surveillance Data. http://www.cdc.gov/asthma/ (accessed 25 November 2013). ">CDC</a>) and 9% to 10% in the UK (<a href="./references#CD010909-bbs2-0031" title="Department of Health. An Outcomes Strategy for COPD and Asthma: NHS Companion Document. www.dh.gov.uk/publications (accessed 3 December 2013). ">DOH 2012</a>). </p> <p>Asthma can present with varying degrees of severity, and in the most severe cases, it can cause daily chronic symptoms and frequent exacerbations (defined as acute worsening of asthma symptoms). Overarching principles of treatment focus on controlling daily symptoms and preventing exacerbations through good education and appropriate use of inhalers. Short‐acting bronchodilators are given to relieve bronchospasm, and corticosteroids for the underlying inflammation; both are usually delivered via inhalers. Depending on the persistence of symptoms, inhalers can be taken regularly (maintenance therapy) or on an as‐needed basis (reliever therapy) (<a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>; <a href="./references#CD010909-bbs2-0033" title="Global Initiative for Asthma(GINA) . Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/ (accessed 20 October 2013). ">GINA 2011</a>). Treatment guidelines recommend preventative management in the community and prompt interventions during exacerbations to reduce mortality and other negative outcomes (such as intubation and hospital admissions). </p> </section> <section id="CD010909-sec-0032"> <h3 class="title" id="CD010909-sec-0032">Description of the intervention</h3> <p>In severe exacerbations of asthma, which can be life threatening, most guidelines recommend the use of oxygen, nebulised or intravenous beta<sub>2</sub>‐agonists, nebulised antimuscarinics and intravenous or oral corticosteroids as first‐line treatment (<a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>; <a href="./references#CD010909-bbs2-0033" title="Global Initiative for Asthma(GINA) . Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/ (accessed 20 October 2013). ">GINA 2011</a>; <a href="./references#CD010909-bbs2-0039" title="National Asthma Council Australia. Asthma Management Handbook. http://www.nationalasthma.org.au/handbook (accessed 25 November 2013). ">NACA 2006</a>; <a href="./references#CD010909-bbs2-0040" title="National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf‎ (accessed 25 November 2013). ">NAEPP 2007</a>). Beta<sub>2</sub>‐agonists are recognised as most effective in relieving bronchospasm (<a href="./references#CD010909-bbs2-0048" title="TeohL , CatesC , HurwitzM , AcworthJP , VanAsperenP , ChangAB . Anticholinergic therapy for acute asthma in children. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003797.pub2] ">Teoh 2012</a>); however, anticholinergic inhalers have also been shown to be effective in the treatment of acute asthma (<a href="./references#CD010909-bbs2-0035" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD000060.pub2] ">Griffiths 2013</a>). When patients show poor response to these, or when they present with a severe or life‐threatening exacerbation, a single dose of intravenous (IV) or nebulised magnesium sulfate (MgSO<sub>4</sub>) can be considered. Nebulised MgSO<sub>4</sub> is the subject of a separate review (<a href="./references#CD010909-bbs2-0041" title="PowellC , DwanK , MilanSJ , BeasleyR , HughesR , Knopp‐SihotaJA , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD003898.pub5] ">Powell 2012</a>). The recommended dosage of IV MgSO<sub>4</sub> in the UK is 1.2 g to 2 g, delivered by infusion over 20 minutes (<a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>), but guidelines differ regarding how and when IV MgSO<sub>4</sub> should be administered (<a href="#CD010909-tbl-0002">Table 1</a>), </p> <div class="table" id="CD010909-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of guideline treatment recommendations in acute asthma (adults)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BTS/SIGN</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GINA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NACA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NAEPP</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxygen</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inhaled beta<sub>2</sub>‐agonist</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inhaled antimuscarinic</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sytemic corticosteroids</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV beta<sub>2</sub>‐agonist</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>if nebulised form cannot be used</p> <p>reliably</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> <p>if no response to inhaled form</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV MgSO<sub>4</sub> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> <p>IV or nebulised</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heliox</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV aminophylline/theophylline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>limited evidence, only after senior consultation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>if inhaled beta<sub>2</sub>‐agonist unavailable </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>as an alternative to IV beta<sub>2</sub>‐agonist </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BTS/SIGN: British Thoracic Society and Scottish Intercollegiate Guidelines Network joint guideline; GINA: Global Initiative for Asthma; IV: Intravenous; NACA: National Asthma Council Australia; NAEPP: National Asthma Education and Prevention Program; ✓: Recommended; x: Not recommended; (✓): Recommended with conditions. </p> </div> </div> <p>National guidelines also vary with respect to definitions of asthma severity and use of additional interventions. <a href="#CD010909-tbl-0002">Table 1</a> offers a summary of treatment strategies recommended by some of these guidelines for the management of acute asthma. </p> </section> <section id="CD010909-sec-0033"> <h3 class="title" id="CD010909-sec-0033">How the intervention might work</h3> <p>Magnesium is an important intracellular and extracellular cation that plays a key role in intracellular enzymatic reactions. Its mechanism of action in the context of an exacerbation of asthma is not fully understood, but several theories have been proposed (<a href="./references#CD010909-bbs2-0044" title="RoweBH . Intravenous and inhaled MgSO4 for acute asthma. The Lancet Respiratory Medicine2013;1(4):276‐7. [DOI: 10.1016/S2213‐2600(13)70097‐3] ">Rowe 2013</a>). It is believed to play a role in bronchial smooth muscle relaxation via its ability to prevent calcium ion movement into smooth muscle cells by blocking the voltage‐dependent calcium channels (<a href="./references#CD010909-bbs2-0034" title="GourgoulianisKI , ChatziparasidisG , ChatziefthimiouA , MolyvdasPA . Magnesium as a relaxing factor of airway smooth muscles. Journal of Aerosol Medicine2001;14(3):301‐7. [PUBMED: 11693841] ">Gourgoulianis 2001</a>; <a href="./references#CD010909-bbs2-0047" title="SpiveyWH , SkobeloffEM , LevinRM . Effect of magnesium chloride on rabbit bronchial smooth muscle. Annals of Emergency Medicine1990;19(10):1107‐12. ">Spivey 1990</a>). Furthermore, some evidence suggests that it may reduce the neutrophilic burst seen with the inflammatory response (<a href="./references#CD010909-bbs2-0029" title="CairnsCB , KrafiM . Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Academic Emergency Medicine1996;3(12):1093‐7. ">Cairns 1996</a>), and that it may be involved in acetylcholine release from cholinergic nerve terminals and histamine release from mast cells (<a href="./references#CD010909-bbs2-0032" title="DominguezLJ , BarbagalloM , DiLorenzoG , DragoA , ScolaS , MoriciG , et al. Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effects of magnesium in asthma. Clinical Science1998;95:137‐42. ">Dominguez 1998</a>). The combination of these properties contributes to relief of airflow obstruction and provides the theoretical basis for the effectiveness of magnesium. </p> </section> <section id="CD010909-sec-0034"> <h3 class="title" id="CD010909-sec-0034">Why it is important to do this review</h3> <p>Acute asthma presentations represent a significant burden on emergency departments (EDs) and carry a substantial mortality risk, with 1143 deaths from asthma reported in the UK in 2010 (<a href="./references#CD010909-bbs2-0027" title="AsthmaUK . Asthma Facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 8 October 2013). ">Asthma UK</a>) and an estimated mortality rate of 1.1 deaths per 100,000 in the USA (<a href="./references#CD010909-bbs2-0030" title="Centers for Disease Control and Prevention. Asthma Surveillance Data. http://www.cdc.gov/asthma/ (accessed 25 November 2013). ">CDC</a>). In the UK, it is thought that "75% of hospital admissions for asthma are avoidable and as many as 90% of the deaths from asthma are preventable" (<a href="./references#CD010909-bbs2-0027" title="AsthmaUK . Asthma Facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 8 October 2013). ">Asthma UK</a>). </p> <p>The financial burden is also significant, with a cost to the National Health Service (NHS) of £1 billion a year, 80% of which is spent on the 20% of people with the most severe disease (<a href="./references#CD010909-bbs2-0031" title="Department of Health. An Outcomes Strategy for COPD and Asthma: NHS Companion Document. www.dh.gov.uk/publications (accessed 3 December 2013). ">DOH 2012</a>). </p> <p>Current guidelines advocate the use of IV MgSO<sub>4</sub> in the treatment of acute severe asthma, but evidence in the literature remains inconclusive (<a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>). New evidence from randomised controlled trials published since the last version of this review may alter the conclusions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010909-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010909-sec-0035"></div> <p>To assess the safety and efficacy of IV MgSO<sub>4</sub> in adults treated for acute asthma in the emergency department. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010909-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010909-sec-0036"></div> <section id="CD010909-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010909-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of any follow‐up duration reported as full text, those published as abstract only and unpublished data. </p> </section> <section id="CD010909-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (defined as over 18 years of age) treated in the ED for acute asthma. If studies recruited both adults and children, we contacted the study authors to try to obtain separate data from adults. </p> </section> <section id="CD010909-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing any dose of IV MgSO<sub>4</sub> versus placebo. People with acute asthma often require multiple medications; therefore we included studies that allowed other treatments (for maintenance, for exacerbation itself or for other co‐morbidities), provided they were not part of the randomly assigned treatment. </p> </section> <section id="CD010909-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010909-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010909-list-0001"> <li> <p>Hospital admissions.</p> </li> </ul> </p> </section> <section id="CD010909-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010909-list-0002"> <li> <p>ED treatment duration.</p> </li> <li> <p>Intensive care unit admissions.</p> </li> <li> <p>Vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation).</p> </li> <li> <p>Spirometry (peak expiratory flow (PEF), forced expiratory volume within one second (FEV<sub>1</sub>)). </p> </li> <li> <p>Validated symptom scores.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>Reporting in the trial of one or more of the outcomes listed here was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD010909-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010909-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD010909-sec-0119">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy described in <a href="./appendices#CD010909-sec-0125">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to the present, and we imposed no restriction on language of publication. </p> </section> <section id="CD010909-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all relevant primary studies and review articles for additional references. We also searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and reported within the review the date this was done. </p> </section> </section> <section id="CD010909-sec-0047"> <h3 class="title" id="CD010909-sec-0047">Data collection and analysis</h3> <section id="CD010909-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Three review authors (KK, LK, CM) independently screened titles and abstracts for inclusion of all citations identified by the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve.' We retrieved the full‐text study reports/publications, and the review authors independently screened the full‐text documents and identified studies for inclusion. We identified and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion, or, if required, we consulted a fourth person. We identified and excluded duplicates and collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a <a href="./references#CD010909-sec-0134" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD010909-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>To record study characteristics and outcome data, we used a data collection form that had been piloted on at least one study in the review. All review authors (KK, LK, CM) extracted study characteristics from included studies, and all review authors independently extracted outcome data. We extracted the following study characteristics. </p> <p> <ul id="CD010909-list-0003"> <li> <p>Methods: study design, duration of observation and follow‐up, details of any 'run‐in' period, number of study centres and locations, withdrawals, dates of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, asthma severity*, diagnostic criteria, co‐morbidities, co‐medications, baseline lung function, inclusion and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, dose, comparison, concomitant and failed treatments, excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported.</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>We noted in the <a href="./references#CD010909-sec-0133" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by reaching consensus or by involving a fourth person. One review author transferred data into the <a href="./references#CD010909-bbs2-0042" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager (RevMan)</a> (version 5.2) file. We double‐checked that data were entered correctly by comparing data presented in the systematic review versus data provided in the study reports. A second review author (LK or CM) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD010909-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>All review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010909-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org2011. ">Higgins 2011</a>), resolving disagreements by discussion. We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD010909-list-0004"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the <a href="#CD010909-sec-0076">Risk of bias in included studies</a> table. We summarised risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for hospital admission may be very different than for a patient‐reported scale). When information on risk of bias was related to unpublished data or correspondence with a trial author, we noted this in the <a href="#CD010909-sec-0076">Risk of bias in included studies</a> table. </p> <p>When considering treatment effects, we took into account the risk of bias for all studies that contributed to that outcome. </p> <section id="CD010909-sec-0051"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to this published protocol and reported deviations from it in the <a href="#CD010909-sec-0131">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD010909-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences (SMDs) with 95% confidence intervals (CIs). If studies reported several validated symptom measures, or if different scales were reported across studies, we analysed the data as SMDs in one analysis to reduce measurement error and to increase precision. We entered data presented as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>When multiple trial arms were reported in a single trial, we included only the relevant arms. When two relevant comparisons from a single study were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD010909-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to hospital rather than number of admissions per adult). </p> </section> <section id="CD010909-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as abstract only). When this was not possible, and when missing data were thought to introduce serious bias, we conducted a sensitivity analysis to explore the impact of including such studies in the overall assessment of results<b>. </b> </p> </section> <section id="CD010909-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. When substantial heterogeneity was identified, we explored possible causes by conducting prespecified subgroup analyses. </p> </section> <section id="CD010909-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>We created and examined a funnel plot to explore possible small‐study and publication biases. We considered the impact of unpublished trials in the GRADE ratings for each outcome. </p> </section> <section id="CD010909-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model and performed a sensitivity analysis with random effects when significant heterogeneity was observed (I² &gt; 30%). </p> <section id="CD010909-sec-0058"> <h5 class="title">Summary of findings table</h5> <p>We created <a href="./full#CD010909-tbl-0001">summary of findings Table for the main comparison</a> for seven of the prespecified outcomes<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies that contributed data to meta‐analyses for the prespecified outcomes (http://www.gradeworkinggroup.org/). We applied methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010909-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org2011. ">Higgins 2011</a>) using GRADEpro software. We justified all decisions to downgrade or upgrade the quality of studies by using footnotes, and we made comments to aid readers' understanding of the review when necessary. </p> </section> </section> <section id="CD010909-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses for the primary outcome, using the formal test for subgroup differences in Review Manager (version 5.2) (<a href="./references#CD010909-bbs2-0042" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager (RevMan)</a>). </p> <p> <ul id="CD010909-list-0005"> <li> <p>Baseline severity (moderate, severe and life‐threatening exacerbations*).</p> </li> <li> <p>Mean age (≤ and &gt; 65 years).</p> </li> <li> <p>Co‐medications (with or without ipratropium bromide**).</p> </li> </ul> </p> <p>*Since there is no single accepted metric for assessment of asthma severity, we extracted baseline data relevant to the severity criteria, as stated in the British Thoracic Society (BTS) guidelines (<a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>), that is, </p> <p> <ul id="CD010909-list-0006"> <li> <p>Clinical features (e.g. ability to complete sentences, respiratory effort, conscious level, signs of exhaustion); </p> </li> <li> <p>Previous intensive care unit admissions;</p> </li> <li> <p>Pulse;</p> </li> <li> <p>Blood pressure;</p> </li> <li> <p>Respiratory rate;</p> </li> <li> <p>Pulse oximetry;</p> </li> <li> <p>Pulsed expiratory flow (PEF); and</p> </li> <li> <p>Arterial blood gas.</p> </li> </ul> </p> <p>Exacerbations of the study populations were labelled as moderate, severe or life threatening on the basis of available data, as judged by an independent assessor who was not involved in the review process and had no other details or results of the trials. Consistent with British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) criteria (<a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>), for which the percentage predicted PEF was available, mean values less than 33% were judged to be life threatening, 33% to 50% severe and over 50% moderate. When this measure was not available, or when the value was close to a cutoff, other criteria were consulted, and the value was then standardised across trials using studies reporting several indices. The decision to perform a subgroup analysis by severity was informed by conclusions drawn in the previous Cochrane review (<a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>) that the intervention may be more effective in cases of severe or life‐threatening asthma. </p> <p>**For co‐medications, we grouped studies by whether investigators gave ipratropium bromide in addition to other treatments (i.e. short‐acting beta<sub>2</sub>‐agonists (SABAs) via a nebuliser or spacer, oral or intravenous corticosteroids). Ipratropium bromide is included in most guidelines, but it is unclear whether this treatment is adopted in all EDs. <a href="./references#CD010909-bbs2-0035" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD000060.pub2] ">Griffiths 2013</a> has demonstrated that it is an effective adjunct to SABAs in children with asthma exacerbation in the acute setting. </p> </section> <section id="CD010909-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We plan to carry out the following sensitivity analyses.</p> <p> <ul id="CD010909-list-0007"> <li> <p>Studies at high risk of bias for blinding.</p> </li> <li> <p>Unpublished data.</p> </li> </ul> </p> <section id="CD010909-sec-0061"> <h5 class="title">Reaching conclusions</h5> <p>We have based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We have avoided making recommendations for practice, and our implications for research suggest priorities for future research and outline remaining uncertainties in this area. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010909-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010909-sec-0062"></div> <section id="CD010909-sec-0063"> <h3 class="title">Description of studies</h3> <p>Full details of the conduct and characteristics of each included study can be found in <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009019.pub2/tables#CD009019-sec2-0020" target="_blank">Characteristics of included studies</a>, and reasons for exclusion when full texts had to be viewed are given in <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009019.pub2/tables#CD009019-sec2-0021" target="_blank">Characteristics of excluded studies</a>. </p> <section id="CD010909-sec-0064"> <h4 class="title">Results of the search</h4> <p>119 references were identified by electronic searches, and 27 additional records were identified by a search of clinicaltrials.gov. Most were excluded upon screening of titles and abstracts (n = 117). Full texts were consulted for the remaining 29 references, and 10 were excluded at this stage, primarily because the study was not conducted in an emergency setting (n = 7). Other reasons for exclusion at this stage were 'study population did not have asthma' (n = 2) and 'no placebo comparison' (n = 1). Several unsuccessful efforts were made to find a trial publication for one additional study (<a href="./references#CD010909-bbs2-0025" title="Abd El KaderF . Ventilatory, cardiovascular and metabolic responses to salbutamol, ipratropium bromide and magnesium sulfate in bronchial asthma: comparative study. Alexandria Medical Journal [The]1997;39(1):43‐64. ">Abd El Kader 1997</a>), which is awaiting classification. The remaining 18 citations related to 14 studies, which were included in this review. Trial flow is presented in <a href="#CD010909-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010909-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010909-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010909-sec-0065"> <h4 class="title">Included studies</h4> <p>Fourteen studies met the inclusion criteria, randomly assigning 2313 people with acute asthma to the comparisons of interest in this review. <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> contributed the largest sample size to the analyses, with 1109 participants randomly assigned to the two intervention groups; in contrast, <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> had the smallest sample size, with 16 participants randomly assigned to the intervention groups. Mean sample size across the included studies was 165. Summary characteristics of the included trials are presented in <a href="#CD010909-tbl-0003">Table 2</a>, and full details of each included study are given in <a href="./references#CD010909-sec-0133" title="">Characteristics of included studies</a>. </p> <div class="table" id="CD010909-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country (centres)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age range (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose (infusion)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐medications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12–85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg/kg (30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV xanthine, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, SB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6–65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 g or 2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>O<sub>2</sub> (if PaO<sub>2</sub> was &lt; 60 mmHg) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thailand (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> if necessary </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scotland (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, nebulised LAMA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA and LAMA, oral corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid (others at physician's discretion), O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA and LAMA, O<sub>2</sub>, IV corticosteroid (discretionary xanthine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, SB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, nebulised LAMA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV metaproterenol, IV xanthine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, SABA aerosol, IV xanthine</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DB: Double‐blind; IV: Intravenous; LAMA: Long‐acting muscarinic antagonist; O<sub>2</sub>: Oxygen; PaO<sub>2</sub>: Partial pressure of oxygen in arterial blood; PC: Placebo‐controlled; R: Randomised; SABA: Short‐acting beta<sub>2</sub>‐agonist; SB: Single‐blind. </p> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> included adults and children, but only 10 participants were younger than 18 years of age; mean age was 36 (± 13.4) years. </p> </div> </div> <section id="CD010909-sec-0066"> <h5 class="title">Design and duration</h5> <p>Most of the studies included in this review were randomised, double‐blinded, placebo‐controlled trials. Of those that were not, two were randomised, single‐blinded, placebo‐controlled trials (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>), one was unblinded with the control group receiving no placebo (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>) and for two trials, the study design was unclear from the information provided (<a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>). For these two studies, the former commented on randomisation but not blinding, and the latter commented on neither randomisation nor blinding, although both studies appeared to include treatment and control groups. </p> <p>The duration of the studies ranged from 45 minutes (<a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>) to 260 minutes (<a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>). Most trials reported outcome data at the end of study treatment periods, but further follow‐up provided in five studies ranged from six hours to one month (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>). Most trials were conducted at a single centre, occurring within one ED, except for <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>, which was done across two EDs in the USA; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>, which took place across 34 EDs in the UK and <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>, which was completed across eight EDs in the USA. </p> </section> <section id="CD010909-sec-0067"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>All studies included participants with an exacerbation of asthma. However differences between studies included the measures used to define an exacerbation, with some using PEF and others using FEV<sub>1</sub>, as well as the time at which these measurements were taken (e.g. on arrival, after initial treatment). </p> <p>PEF was used in seven studies (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>). Two studies (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>) used PEF &lt; 200 L/min, <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> used PEF &lt; 100 or &lt; 25% predicted and <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> specified PEF &lt; 250 L/min or &lt; 50% predicted as the cutoff to indicate an exacerbation. Both <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> and <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> specified PEF &lt; 50% predicted as a cutoff. FEV<sub>1</sub> was used as a criterion for inclusion in four studies (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>), with the cutoff being FEV<sub>1</sub> &lt; 75% predicted (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>) or FEV<sub>1</sub> &lt; 30% (<a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>). <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> used a severity score &gt; 4 (Fischl Index, which is a composite of vital signs, PEF and clinical features). Three studies (<a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>) did not define the criteria used for an exacerbation. </p> <p>Three studies did not define any exclusion criteria (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>). For the remaining studies (n = 11), exclusion criteria were quite consistent and included diabetes mellitus, congestive cardiac disease, hypertension, chronic renal failure, temperature &gt; 38 ºC, pneumonia, pregnancy, participants requiring ventilation and those who did not provide consent. </p> </section> <section id="CD010909-sec-0068"> <h5 class="title">Baseline characteristics of participants</h5> <p>The most common age range used across studies was 18 to 60 years (<a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>). <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> and <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> used a range of 18 to 65 years, <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> 18 to 55 years and <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> 18 to 60 years. Two studies (<a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>) included participants 16 years of age and older, whilst <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> included participants aged 15 to 65 years. Two studies included children and reported age ranges of 12 to 85 years (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>) and six to 65 years (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>). From the studies for which we have only the abstract, <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> did not specify the age of participants, and <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> described participants as 'adults.' </p> <p>Most of the studies were well matched between control and intervention with respect to sex (other than <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>, in which the IV MgSO<sub>4</sub>arm consisted of 50% men compared with 25% in the placebo arm). </p> <p>Only four studies reported ethnicity data (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>). The percentage classified as 'white' ranged from 59% to 100% in three of these (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>), whereas <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> had a greater preponderance of black and Hispanic participants, with only 11% to 14% of participants classified as 'white.' </p> <p>Five studies distinguished smokers (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>), and in all cases the placebo and intervention arms were well matched. The percentage of current smokers within these studies ranged from 7% to 10% in <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>, to 30% to 35% in <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> and <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>. The remainder of the studies (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>) combined current smokers and ex‐smokers, and their proportions ranged from 29% to 50%. </p> <p>Three studies further stratified participants by severity of asthma using American (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>) and British (<a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>) Thoracic Society Guidelines. </p> <p>As stated in the protocol, we categorised study populations on the basis of average severity to conduct a subgroup analysis. Judgements of severity were based on baseline severity characteristics presented in the trials, which are summarised in <a href="#CD010909-tbl-0004">Table 3</a>. The justification for each judgement is given in each study's characteristics table. </p> <div class="table" id="CD010909-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline severity criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category within trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Classification*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 after bronchodilator and corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 35 rpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PEF increasing &lt; 50% or</p> <p>FEV<sub>1</sub> &lt; 75% predicted after single salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sub>2</sub> = 69 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sub>2</sub> = 64 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FEV<sub>1</sub> &lt; 75% predicted after single salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite severity score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 33 rpm</p> <p>HR = 125 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>PEF &lt; 75% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% predicted</p> <p>248 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 102 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41% predicted</p> <p>170 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 109 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23% predicted</p> <p>96 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 116 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown (not in analysis)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One or more of the following: PEF &lt; 50% predicted; RR &gt; 25, HR &gt; 110</p> <p>or cannot complete sentences, but not life threatening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52% predicted</p> <p>433 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 29 rpm</p> <p>HR = 108 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 250 L/min or &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 100 L/min or &lt; 25% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.5 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 31 rpm</p> <p>HR = 110 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 30% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% predicted</p> <p>143 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 102 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 30% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 127 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 L/min, not doubled after beta‐agonist, IV corticosteroid, theophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜150 L/min (from graph)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = ˜ 100 bpm from graph</p> <p>RR = ˜ 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 L/min, not doubled after albuterol × 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>bpm: Beats per minute; FEV<sub>1</sub>: Forced expiratory volume in 1 second; HR: Heart rate; PaO<sub>2</sub>: Partial pressure of oxygen in arterial blood; PEF: Peak expiratory flow; rpm: Respirations per minute;RR: Respiration rate.. </p> <p>Classification for the severity subgroup analysis was assigned by an independent clinician and was cross‐checked with study authors' own judgements. Discrepancies were resolved through discussion. </p> </div> </div> </section> <section id="CD010909-sec-0069"> <h5 class="title">Characteristics of the interventions</h5> <section id="CD010909-sec-0070"> <h6 class="title">IV MgSO<sub>4</sub> </h6> <p>In nine studies a dose of 2 g IV was used, usually in 50 to 100 mL (250 mL in <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>) of 0.9% normal saline or 5% dextrose solution, and was infused over periods ranging from 15 to 30 minutes. </p> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>, <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>, <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> and <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> used a dose of 1.2 g IV MgSO<sub>4</sub> in solutions akin to those mentioned above. <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> used doses calculated by weight of 25 mg/kg; this reflects the broader age range of the participants. </p> </section> <section id="CD010909-sec-0071"> <h6 class="title">Placebo group</h6> <p>All studies had a placebo arm except <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>, in which no placebo was administered to the control group. In all other cases, the same solution that was used to infuse IV MgSO<sub>4</sub> to the treatment group was used as the control solution, in equal volume and over the same time period. <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> added 2 mL sterile water to the control solution, and <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> does not comment on the specific solution used for control but describes it as 'like appearing solution' of equal volume. </p> </section> <section id="CD010909-sec-0072"> <h6 class="title">Co‐medications</h6> <p>A number of other drugs commonly used in acute asthma were co‐administered, and there was a degree of variation in the way this was done. In all trials participants received nebulised SABA (salbutamol and, in one case, metaproterenol sulfate), and most also described the use of oxygen (n = 10) and IV corticosteroids (n = 10) before IV MgSO<sub>4</sub> was given. </p> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> administered oral prednisolone rather than IV corticosteroids, and the form of corticosteroid administered was unclear in <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>, <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> and <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>. In the latter, the decision to administer was based on the severity category to which the participant had been assigned. </p> <p>Use of oxygen was described in 10 studies, although some study authors commented that this was the case only if clinically indicated (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a>). Some authors did not describe the use of oxygen, although they may not have considered this to be a drug treatment requiring mention in the treatment protocol (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>). </p> <p>Three studies administered aminophylline or theophylline (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>), and in <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>, this was guided by serum theophylline levels. </p> <p>Nebulised ipratropium bromide was administered in four studies (<a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>). <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> and <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> commented that other interventions were permitted at the discretion of the treating physician, although they did not specify which ones were permitted. </p> </section> </section> <section id="CD010909-sec-0073"> <h5 class="title">Outcomes and analysis structure</h5> <p>Most studies reported the number of participants who required hospitalisation after treatment (n = 11), but secondary outcomes were inconsistently reported. Three studies reported length of hospital stay for those hospitalised, and only one study at high risk of bias reported the duration of ED treatment (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>). Readmission was reported in <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> and <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> after a week and a month, respectively. </p> <p>Lung function was reported in most of the studies, although this was done in different ways (primarily percentage predicted FEV<sub>1</sub> and PEF, and PEF in litres per minute). Absolute values or changes in FEV<sub>1</sub> (L) were not consistently reported. <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> did not report standard deviation for FEV<sub>1</sub>, but the study was included on the basis of variance derived from the P value reported in the paper. This resulted in an unusually large standard deviation but did not significantly change the final results. </p> <p>In the PEF analysis, we combined three studies reporting mean change from baseline (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>) with five reporting absolute endpoint scores (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>). </p> <p>Four studies reported heart rate, respiratory rate and systolic blood pressure (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>). <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> reported respiratory rate, but the data could not be included because no measure of variance was provided. <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> reported oxygen saturation for participants on and off oxygen separately, but because no other studies reported data, we did not perform a meta‐analysis. Partial pressure was reported in one study (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>), but again this was not formally analysed. These results are summarised narratively. </p> <p>Validated symptom scales generally were not reported in the studies, but four studies reported scores on the Borg Dyspnoea Scale (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>). One additional study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>) measured breathlessness using a visual analogue scale (VAS), which we chose not to analyse, as it was not validated. <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> used the Fischl Index, which is a composite of vital signs, PEF and clinical features. As individual measures were not available, the data were not analysed. </p> <p>A large degree of disparity was noted in the reporting of adverse events; this precluded pooling of data in the meta‐analysis. Five studies reported no information on adverse events (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>), although <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> noted that no major adverse events were reported. <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> and <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> described minor adverse events such as flushing and fatigue, but these were not quantified. Other studies quantified adverse events for the duration of the treatment period, which ranged from 60 to 240 minutes. As such, we summarised information across studies narratively in the results. </p> </section> <section id="CD010909-sec-0074"> <h5 class="title">Subgroup and sensitivity analyses</h5> <p>We conducted subgroup analyses on the primary outcome (hospital admissions) for baseline severity and co‐medications. For severity, 15 groups were identified across the 11 studies reporting the outcome: two moderate, six severe and seven life threatening. </p> <p>We performed the analysis based on whether ipratropium bromide was administered as described in the protocol. <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>, <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>, <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> and <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> were the only studies in which ipratropium bromide was given; three of these are UK studies. However, as information about co‐medications was inconsistently reported (summarised above and in <a href="#CD010909-tbl-0003">Table 2</a>), and it was often unclear when infusions or nebulisers were given, we were conservative in interpretation and have summarised the limitations of the analysis in the discussion. We could not carry out a subgroup analysis based on mean age (≤ and &gt; 65 years), as no trials solely recruited older adults. </p> <p>We also conducted two sensitivity analyses excluding trials at high risk of bias for blinding and those that contributed only unpublished data. <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>, <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> and <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> were removed from the prior, and only <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> from the latter. No full paper was available for <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>, but this study did not report hospital admissions, and although only an abstract was available in English for <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>, the full paper had been published in Turkish, from which we were able to obtain further information. None of the studies provided additional unpublished data for the primary outcome. </p> <p>We added a post‐hoc sensitivity analysis using change from baseline instead of endpoint means from <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>, as baseline imbalances were noted in this study. </p> </section> </section> <section id="CD010909-sec-0075"> <h4 class="title">Excluded studies</h4> <p>Studies that took place outside of an acute setting were excluded, as were those concerned with the effects of nebulised magnesium sulfate (the subject of another review (<a href="./references#CD010909-bbs2-0041" title="PowellC , DwanK , MilanSJ , BeasleyR , HughesR , Knopp‐SihotaJA , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD003898.pub5] ">Powell 2012</a>)). </p> <p>We excluded trials that were exclusively concerned with children, defined as those younger than 18 years of age. These studies will be dealt with in a separate Cochrane review (<a href="./references#CD010909-bbs2-0036" title="GriffithsB , Kew KayleighM , Michell ClareI , KirtchukL . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD011050; CD011050] ">Griffiths 2014</a>). We included studies in which participants were both older and younger than 18. <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> and <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> included participants 16 years of age and older, and we believe that these data are applicable to adults, as we would not expect significant physiological differences between the ages of 16 and 18. <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>, <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> and <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> included participants 12 to 85 years and 15 to 65 years of age, respectively; we endeavoured to obtain data for adults only but were ultimately unsuccessful. Age ranges were unclear in three studies, although the implication was that participants were adults (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>). </p> </section> </section> <section id="CD010909-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of the risk of bias rating for each study and the reasons for each rating, see <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009019.pub2/tables#CD009019-sec2-0020" target="_blank">Characteristics of included studies</a>. A summary of risk of bias judgements by study and domain (allocation generation, allocation concealment, blinding and incomplete data) can be found in <a href="#CD010909-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD010909-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010909-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010909-sec-0077"> <h4 class="title">Allocation</h4> <p>We assessed six studies to be at low risk of bias for random sequence generation and seven for allocation concealment. Both <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> and <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> used random number generation by pharmacy, with blinding of physicians to the allocation. <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> used telephone‐ or Internet‐generated randomisation sequencing, whilst <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> used a random number generator producing a code, and in both studies, numbered treatment packs were prepared in pharmacy before they were used by physicians. <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> used 1:1 randomisation tables, and the pharmacy prepared vials of placebo or IV MgSO<sub>4</sub> with identical appearances and labelled with study IDs. <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> used 1:1 randomisation tables, and study numbers were concealed in envelopes until allocation was completed. </p> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> did not provide sufficient details of random sequence allocation to warrant a low risk bias judgement but adequately described allocation concealment. </p> <p>Two studies (<a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>) detailed adequate randomisation processes (computer‐generated lists); in <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>, this was managed by pharmacy, but no information about allocation concealment was provided, and hence this study was assessed to be at unclear risk in this domain. </p> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>, <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> and <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> commented on randomisation, although no further details were provided and no comment on allocation concealment was made; hence these studies were assessed as unclear in both areas. The same assessment was made with <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>, for which no information about randomisation or allocation concealment was provided. </p> <p>We considered <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> to be at high risk of bias in these domains, as participants were allocated to control or treatment group according to the day of presentation to the department. </p> </section> <section id="CD010909-sec-0078"> <h4 class="title">Blinding</h4> <p>In the domains of both performance and detection bias, we considered most (n = 8) of the included studies to be at low risk of bias (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>). These were described as double‐blinded placebo‐controlled trials, and investigators provided adequate detail about who was blinded and commented that their primary outcomes were non‐subjective assessor‐rated outcomes. </p> <p><a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> described this study as single‐blinded; however through correspondence with the study author, we were able to ascertain that participants and assessors of spirometric and clinical outcomes were blinded, as was the chief resident who made the decision about admission. The individual administering the medication was unblinded; therefore we rated performance bias as 'unclear' and detection bias as 'low risk.' </p> <p>We believe that although <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> performed a double‐blinded study with decoding done at completion of the study, limited detail was provided about who the blinded parties were, and we considered this to be unclear. </p> <p>We have no information for these domains from <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> and <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> and have graded them as also having unclear risk of bias. </p> <p>We assessed that both <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> and <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> are at high risk of bias in these domains. The former study was single‐blinded, and further correspondence with the study author confirmed that only participants were blinded to treatment, allowing for bias in assessment of outcome measures. In <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>, the physicians were unblinded to randomisation, and although neither participants nor respiratory therapists carrying out PEF measures were aware that a study was being conducted, they may have been aware of the treatment received. </p> </section> <section id="CD010909-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>We considered that in half of the included studies (n = 7), the risk of attrition bias was low, and in the other half, the risk was unclear. </p> <p>In studies for which we considered the risk to be low (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>; <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a>), withdrawal rates were clearly documented and numbers were low, with similar rates reported in placebo and control groups. </p> <p>In four studies (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a>), no information was provided about withdrawal rates, hence the reason for considering the risk to be unclear. </p> <p>In <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>, 97 of 217 participants were excluded from analysis, with 80 participants repeat attenders (no comment on the groups to which they had been randomly assigned) and the medical records of 17 participants misplaced. No comment was made about whether there was intention to treat any of the participants who withdrew, although at the point of analysis, numbers in all groups were similar. </p> <p><a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> reports that where repeat attendance to the department was documented, data from only the first presentation were used, but no further commentary was made about withdrawals. </p> <p><a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> provides a very detailed report of participants with protocol violations who were retained in the intention‐to‐treat data set and gives reasons for these inclusions. However, attrition rates were quite high and were not provided for each arm. As such it was unclear whether attrition was balanced between groups, and the study was rated as 'unclear.' </p> </section> <section id="CD010909-sec-0080"> <h4 class="title">Selective reporting</h4> <p>We considered that only five studies demonstrated low risk of bias in reporting of outcome data: <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; and <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>. Although <a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> did not report on arterial blood gas (ABG) results as was planned, other data were well reported, and we believe that the ABG measure was not critical to the study. Both <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> and <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> provided further raw data when directly contacted by the review authors, and this completed the outcomes planned for assessment. The published report of <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> provided data at only one of the prespecified time points and FEV<sub>1</sub> was provided graphically, but the study author provided additional data to the review authors upon request. </p> <p>We considered the following studies to be unclear for risk of reporting bias: <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; and <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>. We have only the abstract for both <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> and <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; The former provided no outcome data, just a written description of investigator conclusions, and the latter provided outcomes at only one of the recorded time points. <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> did provide further raw data to the review authors on request, but this still did not include all time points laid out in the methodology. <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> provided outcome data, but the methodology did not indicate the primary outcome measures selected when the study was designed. <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> provided all primary outcome data at the prespecified time point; however data were also collected at other time points, and this was not reported. </p> <p>We considered that four studies demonstrated high risk of reporting bias. <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> provided only raw admission data, and severity scores were provided only in terms of 'variance.' <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>, <a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> and <a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a> provided raw data for only a subset of outcomes or time points, with remaining results presented graphically or without variance and with no reporting of raw data. </p> </section> <section id="CD010909-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>No additional sources of bias were identified.</p> </section> </section> <section id="CD010909-sec-0082"> <h3 class="title" id="CD010909-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD010909-tbl-0001"><b>Summary of findings for the main comparison</b> IV MgSO<sub>4</sub> for treating adults with acute asthma in the emergency department</a> </p> <section id="CD010909-sec-0083"> <h4 class="title">Primary outcomes</h4> <section id="CD010909-sec-0084"> <h5 class="title">Hospital admissions</h5> <p>Combining 11 studies (n = 972) revealed a significant reduction in hospital admissions compared with placebo (OR 0.75, 95% CI 0.60 to 0.92; high‐quality evidence; <a href="./references#CD010909-fig-0004" title="">Analysis 1.1</a>). Some heterogeneity that was not statistically significant was observed (I<sup>2</sup> = 28%; P value 0.18). In absolute terms, this odds ratio translates to a reduction of seven hospital admissions for every 100 adults (95% CI two to 13 fewer) treated with IV MgSO<sub>4</sub> (<a href="#CD010909-fig-0003">Figure 3</a>). There was no reason to downgrade for any of the five domains in GRADE (risk of bias, inconsistency, indirectness, imprecision, publication bias). Specifically, risk of bias was generally low or unclear across trials, heterogeneity was not significant, trials matched the research question well, confidence intervals were relatively narrow and almost all studies contributed data to the analysis. </p> <div class="figure" id="CD010909-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="In the control group, 57 of 100 people were admitted to hospital, compared with 50 (95% CI 45 to 55) of 100 for the IV MgSO4 group." data-id="CD010909-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the control group, 57 of 100 people were admitted to hospital, compared with 50 (95% CI 45 to 55) of 100 for the IV MgSO<sub>4</sub> group. </p> </div> </div> </div> </section> </section> <section id="CD010909-sec-0085"> <h4 class="title">Secondary outcomes</h4> <section id="CD010909-sec-0086"> <h5 class="title">Intensive care admissions</h5> <p>Evidence from one study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; n = 752) showed no significant difference in admission rates between IV MgSO<sub>4</sub> and placebo (OR 2.03, 95% CI 0.70 to 5.89; moderate‐quality evidence; <a href="./references#CD010909-fig-0005" title="">Analysis 1.2</a>). The same study reported the number of participants admitted to the high dependency unit and showed no significant difference between the two arms (OR 1.05, 95% CI 0.57 to 1.94; moderate‐quality evidence; <a href="./references#CD010909-fig-0006" title="">Analysis 1.3</a>). Both outcomes contained few events from only one study, so they were downgraded twice for imprecision, and the quality of evidence was rated as 'low.' </p> </section> <section id="CD010909-sec-0087"> <h5 class="title">ED treatment duration</h5> <p>Only one study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; n = 452) reported ED treatment duration and found no significant difference between IV MgSO<sub>4</sub> and placebo (MD ‐4.00, 95% CI ‐37.02 to 29.02; low‐quality evidence; <a href="./references#CD010909-fig-0007" title="">Analysis 1.4</a>). The outcome was downgraded for risk of bias and imprecision. </p> </section> <section id="CD010909-sec-0088"> <h5 class="title">Length of hospital stay (days)</h5> <p>Combining three studies reporting the outcome (n = 949) revealed no significant difference in time spent in hospital between the IV MgSO<sub>4</sub> and placebo groups (MD ‐0.03, 95% CI ‐0.33 to 0.27; low‐quality evidence; <a href="./references#CD010909-fig-0008" title="">Analysis 1.5</a>). The evidence was downgraded for risk of bias and inconsistency (I<sup>2</sup> = 53%; P value 0.10). As I<sup>2</sup> was over the 30% defined in the protocol, we performed a sensitivity analysis using random effects, which did not change the conclusions (MD ‐0.16, 95% CI ‐0.68 to 0.37). </p> </section> <section id="CD010909-sec-0089"> <h5 class="title">Readmission</h5> <p>Too few events were described in only two studies to indicate whether IV MgSO<sub>4</sub> had an effect on readmission to hospital compared with placebo (OR 2.30, 95% CI 0.66 to 7.99; moderate‐quality evidence; <a href="./references#CD010909-fig-0009" title="">Analysis 1.6</a>). No statistical heterogeneity was noted between the studies (I<sup>2</sup> = 0%; P value 0.34), but the outcome was downgraded for imprecision. </p> </section> <section id="CD010909-sec-0090"> <h5 class="title">Vital signs</h5> <section id="CD010909-sec-0091"> <h6 class="title">Heart rate</h6> <p>Combining four studies (n = 1195) showed a small significant reduction in heart rate with IV MgSO<sub>4</sub> compared with placebo (MD ‐2.37, 95% CI ‐4.13 to ‐0.61; moderate‐quality evidence; <a href="./references#CD010909-fig-0010" title="">Analysis 1.7</a>). However a high degree of heterogeneity was observed, which was statistically significant and warranted downgrading (I<sup>2</sup> = 78%; P value 0.004). A sensitivity analysis using random effects decreased precision significantly, with confidence intervals including both significant benefit and potential harm of IV MgSO<sub>4</sub> (MD ‐2.61, 95% CI ‐6.58 to 1.35). </p> </section> <section id="CD010909-sec-0092"> <h6 class="title">Respiratory rate</h6> <p>When five studies were combined (n = 1276), IV MgSO<sub>4</sub> did not show a significant reduction in respiratory rate compared with placebo (MD ‐0.28, 95% CI ‐0.77 to 0.20; moderate‐quality evidence; <a href="./references#CD010909-fig-0011" title="">Analysis 1.8</a>). Heterogeneity was not significant (I<sup>2</sup> = 1%; P value 0.39), but the evidence was downgraded for imprecision because confidence intervals included significant benefit and potential harm of the treatment. </p> </section> <section id="CD010909-sec-0093"> <h6 class="title">Systolic blood pressure</h6> <p>Four studies (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; n = 1264) reporting systolic blood pressure showed no difference between IV MgSO<sub>4</sub> and placebo (MD 0.08, 95% CI ‐1.89 to 2.05; moderate‐quality evidence; <a href="./references#CD010909-fig-0012" title="">Analysis 1.9</a>). Heterogeneity was high, and although it was not statistically significant, authors considered it large enough to warrant downgrading for inconsistency (I<sup>2</sup> = 51%; P value 0.11). A sensitivity analysis using random effects did not change the conclusions (MD ‐0.73, 95% CI ‐4.13 to 2.67). </p> <p><b>Oxygen saturations</b> </p> <p>One study reported outcomes separately for those receiving and those not receiving oxygen (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>). This outcome was not reported in other studies; therefore we were unable to meta‐analyse the data. </p> </section> </section> <section id="CD010909-sec-0094"> <h5 class="title">Spirometry</h5> <section id="CD010909-sec-0095"> <h6 class="title">FEV<sub>1</sub> (% predicted) </h6> <p>When four studies were combined (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>) (n = 523), significant improvement in percentage predicted FEV<sub>1</sub> was seen in the IV MgSO<sub>4</sub> group compared with the placebo group (MD 4.41, 95% CI 1.75 to 7.06; high‐quality evidence; <a href="./references#CD010909-fig-0013" title="">Analysis 1.10</a>). No significant heterogeneity was noted among studies (I<sup>2</sup>= 14%; P value 0.33). </p> <p>During data analysis, reported standard deviations in <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> were outliers and appeared to be more consistent with standard error values; the author confirmed that this was the case. In addition, <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> reported no standard deviations; therefore the standard error of the mean was calculated from the graphs. </p> </section> <section id="CD010909-sec-0096"> <h6 class="title">PEF (% predicted)</h6> <p>Three studies (<a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; n = 1129) reported PEF (% predicted) and showed a statistically significant improvement in PEF with IV MgSO<sub>4</sub> compared with placebo (MD 4.78, 95% CI 2.14 to 7.43; high‐quality evidence; <a href="./references#CD010909-fig-0014" title="">Analysis 1.11</a>). Heterogeneity between studies was high but was not statistically significant (I<sup>2</sup> = 45%; P value 0.16), so the evidence was not downgraded. A sensitivity analysis with random effects did not change our conclusions (MD 5.17, 95% CI 1.15 to 9.19). On the basis of observed baseline imbalances in the largest study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>), a second sensitivity analysis using change from baseline instead of endpoint means substantially reduced the effect (MD 1.57, 95% CI ‐0.55 to 3.69; I<sup>2</sup> = 79%, P = 0.009; <a href="./references#CD010909-fig-0021" title="">Analysis 2.5</a>). </p> </section> <section id="CD010909-sec-0097"> <h6 class="title">PEF (L/min)</h6> <p>Combining eight studies (n = 1460) revealed that IV MgSO<sub>4</sub> improved PEF compared with placebo (MD 17.40, 95% CI 8.64 to 26.17; moderate‐quality evidence; <a href="./references#CD010909-fig-0015" title="">Analysis 1.12</a>). However statistically significant heterogeneity between the studies (I<sup>2</sup> = 50%; P value 0.05) warranted downgrading. A sensitivity analysis with random effects did not change our conclusions (MD 18.35, 95% CI 4.12 to 32.58). As with the percentage PEF predicted analysis, a second sensitivity analysis using <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> change from baseline substantially reduced the magnitude of effect (MD 9.44, 95% CI 2.07 to 16.81; I<sup>2</sup> = 68%, P = 0.003; <a href="./references#CD010909-fig-0022" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD010909-sec-0098"> <h5 class="title">Validated symptom scores</h5> <p>Five studies used symptom scales, all measuring breathlessness (n = 1237). The Borg Dyspnoea Scale was used by four studies (<a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>), and <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> used a VAS for breathlessness. Data for the Borg Dyspnoea Scale revealed no significant change with IV MgSO<sub>4</sub> compared with placebo (MD ‐0.22, 95% CI ‐0.55 to 0.12; high‐quality evidence; <a href="./references#CD010909-fig-0016" title="">Analysis 1.13</a>), and no significant heterogeneity between studies was noted (I<sup>2</sup> = 0%; P value 0.82). </p> <p>Similarly, <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> reported no significant change in VAS score with IV MgSO<sub>4</sub> compared with placebo (MD ‐3.00, 95% CI ‐7.09 to 1.09). </p> </section> <section id="CD010909-sec-0099"> <h5 class="title">Adverse events</h5> <p>The most commonly cited adverse events were flushing, fatigue, nausea and headache; some study authors also commented on hypotension. </p> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> reported flushing in 42% of those receiving IV MgSO<sub>4</sub> versus no flushing in the placebo group. Although paraesthesia, vertigo and hypotension were also reported, no marked differences between treatment and placebo arms were observed. </p> <p><a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> reported that 58% of those receiving IV MgSO<sub>4</sub> reported adverse events, including the sensation of flushing, fatigue and burning at the IV site, with one participant experiencing transient urticaria in the upper extremities. </p> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> reported minor adverse events in 8% of those receiving IV MgSO<sub>4</sub> (headache, flushing, dizziness), with only one participant in the placebo arm reporting flushing (1.5%). </p> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> reported the rate of adverse events (death, arrhythmia, cardiac arrest, non‐invasive ventilation, intubation, other) as 13% in the treatment group compared with 10% in the placebo group, although these rates fall almost entirely in the 'other' category. One death of an unspecified cause (1%) was reported in the IV MgSO<sub>4</sub> group compared with none in the placebo group. No other trials reported deaths. <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> reported commonly cited adverse events as a separate category and revealed a statistically significant increase in adverse events in the IV MgSO<sub>4</sub> group (OR 1.68, 95% CI 1.07 to 2.63; P value 0.025). </p> <p>Both <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> and <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> reported that the difference between rates of adverse events (including deep tendon reflexes) among participants given IV MgSO<sub>4</sub> versus placebo was not statistically significant. </p> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> reported higher rates of fatigue (32% vs 11%), warmth (26%) and lightheadedness (5%) in the IV MgSO<sub>4</sub> group, but the numbers in this study were small. </p> <p>With respect to blood pressure, <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> reported hypotension in 5% versus 3% of participants in the treatment versus placebo groups, whilst <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> reported 8% versus 6%, respectively. <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> reported a non‐significant trend for decreasing blood pressure at 60 minutes, and <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> reported no hypotension. </p> </section> </section> <section id="CD010909-sec-0100"> <h4 class="title">Subgroup analyses</h4> <section id="CD010909-sec-0101"> <h5 class="title">Baseline severity (moderate, severe and life‐threatening exacerbations)</h5> <p>The test for subgroup differences revealed no statistical heterogeneity between the three severity subgroups (I<sup>2</sup> = 0%; P value 0.73), and between‐trial heterogeneity was significant within all three subgroups (I<sup>2</sup> = 50%; P value 0.01). </p> </section> <section id="CD010909-sec-0102"> <h5 class="title">Mean age (≤ and &gt; 65 years)</h5> <p>Most studies included participants over age 65, but all population mean ages were much lower than the cutoff. As we did not have access to individual participant data within the trials, we were unable to draw any conclusions regarding potential differential effects of IV MgSO<sub>4</sub> due to age. </p> </section> <section id="CD010909-sec-0103"> <h5 class="title">Co‐medications (with and without nebulised ipratropium bromide)</h5> <p>The test for subgroup differences showed no significant differences between the four studies that administered nebulised ipratropium bromide as a co‐medication and those that did not (I<sup>2</sup> = 0%; P value 0.82). Between‐trial heterogeneity was not statistically significant within either of the two subgroups (I<sup>2</sup> = 28%; P value 0.18). </p> </section> </section> <section id="CD010909-sec-0104"> <h4 class="title">Sensitivity analysis</h4> <section id="CD010909-sec-0105"> <h5 class="title">Studies at high risk of bias for blinding</h5> <p>When three studies that were given a 'high' or 'unclear' rating for blinding were removed (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>), the pooled effect for hospital admissions was slightly larger in favour of IV MgSO<sub>4</sub> (OR 0.72, 95% CI 0.57 to 0.91; <a href="./references#CD010909-fig-0019" title="">Analysis 2.3</a>). Heterogeneity was slightly larger than in the main analysis, but this difference was not statistically significant (I<sup>2</sup> = 35%; P value 0.15). </p> </section> <section id="CD010909-sec-0106"> <h5 class="title">Unpublished data</h5> <p>Of the two studies for which only a conference abstract was available, one reported hospital admissions (<a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>). When this study was removed from the primary outcome, the magnitude of the effect in favour of IV MgSO<sub>4</sub> was slightly increased (OR 0.73, 95% CI 0.58 to 0.91), but this did not change the conclusions. Some heterogeneity that was not significant was reported (I<sup>2</sup> = 32%; P value 0.15). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010909-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010909-sec-0107"></div> <section id="CD010909-sec-0108"> <h3 class="title" id="CD010909-sec-0108">Summary of main results</h3> <p>Fourteen studies met the inclusion criteria, randomly assigning 2313 people with acute asthma to the comparisons of interest in this review. A recent large study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>) accounted for a large proportion of the total number of participants (n = 752). </p> <p>The included studies were mostly randomised, double‐blinded trials comparing 1.2 g or 2 g IV MgSO<sub>4</sub> versus a matching placebo infusion. All of these studies included participants who had an exacerbation of asthma, although definitions and inclusion criteria varied. Ten studies included only adults; four included adults and children and were included because the mean age was over 18 years. Inclusion criteria varied, and studies assigned a level of severity to participants, which we then verified against <a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a> criteria, confirming that all studies included exacerbations of at least moderate severity. </p> <p>Eleven studies could be included in the primary analysis and showed that IV MgSO<sub>4</sub> reduced hospital admissions compared with placebo (OR 0.75, 95% CI 0.60 to 0.92; I<sup>2</sup> = 28%; P value 0.18; n = 972; high‐quality evidence). In absolute terms, this odds ratio translates into a reduction of seven hospital admissions for every 100 adults (95% CI two to 13 fewer) treated with IV MgSO<sub>4</sub> (<a href="#CD010909-fig-0003">Figure 3</a>). The test for subgroup differences did not reveal statistical heterogeneity between the three severity subgroups (I<sup>2</sup> = 0%; P value 0.73), or between the four studies that administered nebulised ipratropium bromide as a co‐medication and those that did not (I<sup>2</sup> = 0%;, P value 0.82). Sensitivity analyses removing unpublished data and studies at high risk for blinding from the primary analysis did not change conclusions; this increased our confidence in the effect. </p> <p>Within the secondary outcomes, evidence of high and moderate quality across three spirometric indices suggested some improvement in lung function with IV MgSO<sub>4</sub>; however the clinical significance of the size of these effects is uncertain, and baseline imbalances in the largest study reduced our confidence in some of the findings. Although close, the mean difference in PEF (L/min) found in this meta‐analysis did not reach the minimal clinically important difference (MCID) defined by <a href="./references#CD010909-bbs2-0045" title="SantanelloNC , ZhangJ , SeidenbergB , ReissTF , BarberBL . What are minimal important changes for asthma measures in a clinical trial?. European Respiratory Journal1999;14(1):23‐7. ">Santanello 1999</a> (18.79 L/min). There are no accepted MCIDs for the percentage predicted measures reported in most of the trials. Mean FEV<sub>1</sub> in litres, for which an MCID does exist, was reported in only two of the 14 trials. </p> <p>No difference between IV MgSO<sub>4</sub> and placebo was found for most of the non‐spirometric secondary outcomes, all of which were rated of low or moderate quality (intensive care admissions, ED treatment duration, length of hospital stay, readmission, respiration rate, systolic blood pressure). </p> <p>Adverse events were inconsistently reported and were not meta‐analysed. The most commonly cited adverse events in the IV MgSO<sub>4</sub> groups were flushing, fatigue, nausea and headache and hypotension. However we found no significant difference in blood pressure between the IV MgSO<sub>4</sub> and placebo groups. </p> </section> <section id="CD010909-sec-0109"> <h3 class="title" id="CD010909-sec-0109">Overall completeness and applicability of evidence</h3> <p>A large degree of variation between prescribing procedures was evident in the trials, but doses used in the included studies are in accord with current <a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a>, <a href="./references#CD010909-bbs2-0033" title="Global Initiative for Asthma(GINA) . Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/ (accessed 20 October 2013). ">GINA 2011</a> and <a href="./references#CD010909-bbs2-0039" title="National Asthma Council Australia. Asthma Management Handbook. http://www.nationalasthma.org.au/handbook (accessed 25 November 2013). ">NACA 2006</a> guidelines. However, the treatment protocols differed as to when the decision to administer IV MgSO<sub>4</sub> was made; the dosage, frequency and form of co‐medications and the order in which the medications were administered in relation to one another. We suspect that differences between individual EDs both within and among countries were significant, and insufficient reporting in the trials themselves further complicated interpretation of the subgroup analysis for co‐medications. As such, although no evidence suggested a difference in the efficacy of IV MgSO<sub>4</sub> delivered in settings where ipratropium bromide was prescribed, we cannot exclude the possibility that other combinations of co‐medications may significantly alter the effectiveness of IV MgSO<sub>4</sub>. Moreover, as almost all of the studies administered short‐acting beta<sub>2</sub>‐agonists, oxygen and IV corticosteroids before MgSO<sub>4</sub>, the evidence is suitably applied to situations for which these medications have already been prescribed. Doses of magnesium used and method and rate of delivery were relatively consistent across studies (1.2 g to 2 g via 15 to 30‐minute infusion), so it is not clear whether the same effect would be observed with alternative administrations (e.g. higher dose, bolus). </p> <p>The definition of hospital admission may have varied between the healthcare settings in which these studies were carried out, and this was not clearly defined in the studies. We accept that variation exists in the broader health and economic environments and in health infrastructures, such as the use of clinical decision making or observation wards, and that this is likely to have influenced the decision to admit. This variation is likely to have introduced heterogeneity in the primary outcome. </p> <p>The previous version of this review (<a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>) suggested the possibility of greater efficacy of treatment in more severe exacerbations; this partially informed our decision to perform a subgroup analysis based on severity. We did not find a statistically significant difference between the three severity subgroups; however, the method that we used to allocate baseline severity had limitations. We based this classification on <a href="./references#CD010909-bbs2-0028" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 8 October 2013). ">BTS/SIGN 2012</a> criteria, but reporting of baseline metrics on which this guidance is based was insufficient in several studies. In studies that subdivided the population on the basis of severity (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>), subgroups with a more severe condition gained greater benefit with respect to hospital admission. This suggests that within‐study subgroups may serve as a more reliable way of assessing severity as an effect modifier by controlling for differences in other variables that may exist between study protocols. </p> <p>We were unable to draw conclusions regarding the potential effects of age on study outcomes, as none of the studies recruited older adults. It is possible that diagnosis in this age group would be complicated by important co‐morbidities (e.g. chronic obstructive pulmonary disease (COPD)), and that these might also affect the safety and effectiveness of IV MgSO<sub>4</sub>. As such, it is likely that the conclusions of this review are not applicable to this population, or to children younger than the age of 12. </p> <p>Several outcomes showed significant statistical heterogeneity among studies that was not accounted for by subgrouping results by severity of exacerbations (heart rate (HR), systolic blood pressure (BP), PEF in L/min, length of hospital stay). For HR, systolic BP and PEF in L/min, variation may be explained in part by when and how the measurement was taken, measurement error and the influence of co‐medications. Length of hospital stay is highly dependent on local hospital guidelines and procedures. </p> <p>We were unable to meta‐analyse data related to adverse events and therefore could not draw conclusions about the safety of IV MgSO<sub>4</sub> in asthma. Some commonly cited adverse events were consistently reported among the studies; however, the methods of recording adverse events appeared unsystematic. </p> </section> <section id="CD010909-sec-0110"> <h3 class="title" id="CD010909-sec-0110">Quality of the evidence</h3> <p>We used GRADEpro software to assess the quality of all outcomes; this assessment is summarised in the text and in the <a href="./full#CD010909-tbl-0001">summary of findings Table for the main comparison</a>. Most outcomes were not downgraded for risk of bias, and in the two cases in which this was done, the decision was related primarily to insufficient blinding. It is unclear how this may have affected results for the primary outcome (i.e. decision to admit), but a sensitivity analysis excluding studies in which blinding was insufficient or unclear showed that this bias is unlikely to have significantly affected the pooled estimate. </p> <p>Several outcomes were downgraded for inconsistency, that is, statistical heterogeneity, between studies. In these cases we performed sensitivity analyses using a random‐effects model, which did not alter conclusions. The clinical source of the statistical heterogeneity remains unclear in most cases, as planned subgroup analyses were performed only on the primary outcome. Most of the secondary outcomes for which heterogeneity was observed contained a small number of studies; therefore it is unlikely that subgrouping of results would have allowed a meaningful distinction between severity or co‐medication subgroups. </p> <p>Studies included in this review were directly relevant to our review question with respect to participants recruited, interventions and comparisons provided, healthcare setting selected, and outcome measures used, so none of the evidence was downgraded for indirectness. </p> <p>Four outcomes were downgraded for imprecision on the basis of their wide confidence intervals (intensive care unit (ICU) admission, ED treatment duration, PEF in L/min, respiratory rate (RR)). In each case the review authors made a clinical judgement regarding the minimal clinically important difference in relation to the confidence intervals. Moreover, with the exception of ED treatment duration, evidence from related outcomes (e.g. other spirometric measures) helped us draw conclusions when imprecision was due to a small number of participants or events. </p> <p>No outcomes were downgraded for publication bias, although several of the secondary outcomes included a small number of studies. No incidences were identified in which studies stated outcomes and failed to report them, but this was generally a result of insufficient reporting of intended outcomes and the fact that the studies could not be linked to trial registrations. Most studies were conducted before adherence to trial registration or reporting standards was common practice, so in most cases we were unable to definitively judge whether the evidence was compromised as a result of deliberate or inadvertent selective reporting. </p> <p>To resolve uncertainties related to risk of bias and missing data, we made an effort to contact all study authors. We received additional data from four of these authors (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>), were unable to obtain current contact details for two (<a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>) and received no response from the remaining eight. </p> </section> <section id="CD010909-sec-0111"> <h3 class="title" id="CD010909-sec-0111">Potential biases in the review process</h3> <p>We made every effort to adhere to Cochrane methods during the review process. All study characteristics and numerical data were extracted by at least two review authors, and discrepancies were resolved through discussion. The same was true for risk of bias ratings, and none of the review authors have conflicting interests. </p> <p>We performed relatively broad searches that were screened by at least two review authors independently, and we included studies regardless of language of publication. As a result, It is unlikely that any published studies were missed during study selection. In addition, review authors attempted to contact all study authors to clarify study methodology or to obtain additional data when details were not included in the published reports. We received detailed replies and additional data from four study authors, but in most cases, it was unclear whether study authors had failed to receive the request or were simply unable to provide the information required. </p> <p>The subgroup analysis based on exacerbation severity introduced the potential for internal bias, despite efforts to remove bias by consultation with an independent fourth party. Although we were transparent in the method of classification, an element of subjectivity due to reporting standards was noted in some trials; this reduced our confidence in the subgroup findings. </p> </section> <section id="CD010909-sec-0112"> <h3 class="title" id="CD010909-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>Our literature search identified five systematic reviews with meta‐analyses comparing use of IV MgSO<sub>4</sub> versus placebo in adults with acute asthma (<a href="./references#CD010909-bbs2-0026" title="AlterHJ , KoepsellTD , HiltyWM . Intravenous magnesium as an adjuvant in acute bronchospasm: a meta‐analysis. Annals of Emergency Medicine2000;36(3):191‐7. ">Alter 2000</a>; <a href="./references#CD010909-bbs2-0038" title="MohammedS , GoodacreS . Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta‐analysis. Emergency Medicine Journal2007;24:823‐30. ">Mohammed 2007</a>; <a href="./references#CD010909-bbs2-0043" title="RodrigoG , RodrigoC , BurschtinO . Efficacy of magnesium sulfate in acute adult asthma: a meta‐ analysis of randomized trials. American Journal of Emergency Medicine2000;18(2):216‐21. ">Rodrigo 2000</a>; <a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>; <a href="./references#CD010909-bbs2-0046" title="ShanZ , RongY , YangW , WangD , YaoP , XieJ , LiuL . Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta‐analysis. Respiratory Medicine2013;107(3):321‐30. ">Shan 2013</a>). One of these, <a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>, was a previous Cochrane review, and <a href="./references#CD010909-bbs2-0046" title="ShanZ , RongY , YangW , WangD , YaoP , XieJ , LiuL . Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta‐analysis. Respiratory Medicine2013;107(3):321‐30. ">Shan 2013</a>, the most recent research synthesis, included the greatest number of trials (n = 16), 10 of which are included in this review. </p> <p>The main outcomes analysed were hospital admissions and spirometric data. None of the existing reviews found a statistically significant reduction in hospital admissions across all severity subgroups. However <a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a> found a significant reduction in hospital admissions within the more severe group (OR 0.10, 95% CI 0.04 to 0.27) and suggested that IV MgSO<sub>4</sub> might play a role in these more severe exacerbations. Hospital admission data for <a href="./references#CD010909-bbs2-0046" title="ShanZ , RongY , YangW , WangD , YaoP , XieJ , LiuL . Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta‐analysis. Respiratory Medicine2013;107(3):321‐30. ">Shan 2013</a> were on the border of statistical significance (P value 0.06). </p> <p><a href="http://archie.cochrane.org/sections/documents/view?version=z1402211615080547247226957334645%26format=REVMAN#REF-Alter-2000" target="_blank">Alter 2000</a> and <a href="http://archie.cochrane.org/sections/documents/view?version=z1402211615080547247226957334645%26format=REVMAN#REF-Shan-2013" target="_blank">Shan 2013</a> reported significant improvement in pooled spirometric measures for those receiving IV MgSO<sub>4</sub>, whilst <a href="http://archie.cochrane.org/sections/documents/view?version=z1402211615080547247226957334645%26format=REVMAN#REF-Mohammed-2007" target="_blank">Mohammed 2007</a> reported weak evidence to support this (SMD 0.25, 95% CI ‐0.01 to 0.51; P value 0.05). Pooled analyses in <a href="./references#CD010909-bbs2-0043" title="RodrigoG , RodrigoC , BurschtinO . Efficacy of magnesium sulfate in acute adult asthma: a meta‐ analysis of randomized trials. American Journal of Emergency Medicine2000;18(2):216‐21. ">Rodrigo 2000</a> and <a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a> showed no significant improvement in lung function for those given IV MgSO<sub>4</sub>. </p> <p>In keeping with these reviews, we found evidence that IV MgSO<sub>4</sub> improves lung function on a variety of spirometric measures. However, our findings differ in that when all data regardless of severity criteria were pooled, a statistically significant reduction in hospital admissions was seen among those treated with IV MgSO<sub>4</sub>. We did not draw firm conclusions regarding the extent to which severity of exacerbation affects the efficacy of IV MgSO<sub>4</sub> because differences in the ways the studies were conducted made it difficult to assess the effect of exacerbation severity independent of other effect moderators. </p> <p>Several reasons may account for the discrepancies between our conclusions and those of previous evidence syntheses. Unlike some previous systematic reviews (<a href="./references#CD010909-bbs2-0026" title="AlterHJ , KoepsellTD , HiltyWM . Intravenous magnesium as an adjuvant in acute bronchospasm: a meta‐analysis. Annals of Emergency Medicine2000;36(3):191‐7. ">Alter 2000</a>; <a href="./references#CD010909-bbs2-0038" title="MohammedS , GoodacreS . Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta‐analysis. Emergency Medicine Journal2007;24:823‐30. ">Mohammed 2007</a>; <a href="./references#CD010909-bbs2-0050" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , CamargoCA . Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001490] ">Rowe 2009</a>; <a href="./references#CD010909-bbs2-0046" title="ShanZ , RongY , YangW , WangD , YaoP , XieJ , LiuL . Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta‐analysis. Respiratory Medicine2013;107(3):321‐30. ">Shan 2013</a>), our inclusion criteria did not include paediatric trials. Several additional trials have been published since the previous version of this review, and this warranted synthesising of data for adults separately from data for children (<a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a>; <a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>; <a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a>; <a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a>; <a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a>; <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>; <a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a>; <a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a>). One of these trials, <a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>, is a recent randomised controlled trial with a large sample size; it accounted for a significant proportion of the total weight in several of our analyses. Evidence for the use of IV MgSO<sub>4</sub> in the paediatric population will be analysed in a separate Cochrane review, which is currently in production. Some previous syntheses have included trials of nebulised magnesium sulfate (<a href="./references#CD010909-bbs2-0038" title="MohammedS , GoodacreS . Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta‐analysis. Emergency Medicine Journal2007;24:823‐30. ">Mohammed 2007</a>; <a href="./references#CD010909-bbs2-0043" title="RodrigoG , RodrigoC , BurschtinO . Efficacy of magnesium sulfate in acute adult asthma: a meta‐ analysis of randomized trials. American Journal of Emergency Medicine2000;18(2):216‐21. ">Rodrigo 2000</a>; <a href="./references#CD010909-bbs2-0046" title="ShanZ , RongY , YangW , WangD , YaoP , XieJ , LiuL . Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta‐analysis. Respiratory Medicine2013;107(3):321‐30. ">Shan 2013</a>), which we did not include, as this is the subject of an existing Cochrane review (<a href="./references#CD010909-bbs2-0041" title="PowellC , DwanK , MilanSJ , BeasleyR , HughesR , Knopp‐SihotaJA , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD003898.pub5] ">Powell 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010909-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010909-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010909-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="In the control group, 57 of 100 people were admitted to hospital, compared with 50 (95% CI 45 to 55) of 100 for the IV MgSO4 group." data-id="CD010909-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>In the control group, 57 of 100 people were admitted to hospital, compared with 50 (95% CI 45 to 55) of 100 for the IV MgSO<sub>4</sub> group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 1 Hospital admissions." data-id="CD010909-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 1 Hospital admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 2 Intensive care unit (ICU) admissions." data-id="CD010909-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 2 Intensive care unit (ICU) admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 3 High dependency unit (HDU) admissions." data-id="CD010909-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 3 High dependency unit (HDU) admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 4 ED treatment duration (minutes)." data-id="CD010909-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 4 ED treatment duration (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 5 Length of hospital stay (days)." data-id="CD010909-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 5 Length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 6 Readmission." data-id="CD010909-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 6 Readmission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 7 Heart rate (bpm)." data-id="CD010909-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 7 Heart rate (bpm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 8 Respiratory rate (breaths/min)." data-id="CD010909-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 8 Respiratory rate (breaths/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 9 Systolic blood pressure (mmHg)." data-id="CD010909-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 9 Systolic blood pressure (mmHg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 10 FEV1 (% predicted)." data-id="CD010909-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 10 FEV<sub>1</sub> (% predicted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 11 PEF (% predicted)." data-id="CD010909-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 11 PEF (% predicted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 12 PEF (L/min)." data-id="CD010909-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 12 PEF (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IV MgSO4 versus placebo, Outcome 13 Borg Dyspnoea Scale score." data-id="CD010909-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 IV MgSO<sub>4</sub> versus placebo, Outcome 13 Borg Dyspnoea Scale score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 1 Hospital admissions (by severity)." data-id="CD010909-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 1 Hospital admissions (by severity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 2 Hospital admissions (by co‐medications)." data-id="CD010909-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 2 Hospital admissions (by co‐medications). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 3 Hospital admissions (risk of bias sensitivity)." data-id="CD010909-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 3 Hospital admissions (risk of bias sensitivity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 4 Hospital admissions (unpublished sensitivity)." data-id="CD010909-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 4 Hospital admissions (unpublished sensitivity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 5 PEF % predicted (Goodacre change score sensitivity)." data-id="CD010909-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 5 PEF % predicted (Goodacre change score sensitivity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010909-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/urn:x-wiley:14651858:media:CD010909:CD010909-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_t/tCD010909-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 6 PEF L/min (Goodacre change score sensitivity)." data-id="CD010909-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 IV MgSO<sub>4</sub> versus placebo (subgroup and sensitivity analyses), Outcome 6 PEF L/min (Goodacre change score sensitivity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/media/CDSR/CD010909/image_n/nCD010909-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010909-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IV MgSO4 for treating adults with acute asthma in the emergency department</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>IV MgSO<sub>4</sub> for treating adults with acute asthma in the ED</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with acute asthma<br/> <b>Settings:</b> emergency department<br/> <b>Intervention:</b> IV MgSO<sub>4</sub> </p> <p><b>Comparions:</b> placebo </p> <p>Both intervention and placebo groups received oxygen, short‐acting beta<sub>2</sub>‐agonists and oral or intravenous steroids before the infusion. </p> <p>Measurements were taken between 60 and 240 minutes after the start of the infusion.</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IV MgSO<sub>4</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> <br/> (442 to 549) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.75</b> <br/> (0.60 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1769<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit (ICU) admissions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.03</b> <br/> (0.7 to 5.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>752<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay in the control groups was<br/> <b>2.73 days</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean length of hospital stay in the intervention groups was<br/> <b>0.03 days lower</b> <br/> (0.33 lower to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>949<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7,8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ED treatment duration (minutes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean duration in the placebo group was</p> <p><b>228 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ED treatment duration in the intervention groups was<br/> <b>4 minutes lower</b> <br/> (37.02 lower to 29.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>9,10,11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> in the placebo group was </p> <p><b>50% predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> (% predicted) in the intervention groups was<br/> <b>4.41 higher</b> <br/> (1.75 to 7.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>523<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>12,13,14</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PEF (L/min)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean PEF in the placebo group was</p> <p><b>239 L/min</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean PEF in the intervention groups was<br/> <b>17.4 L/min higher</b> <br/> (8.64 to 26.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1460<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>15,16,17</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory rate (breaths/min)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean respiration rate in the placebo group was</p> <p><b>20.7 respirations/min</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean respiratory rate in the intervention groups was<br/> <b>0.28 breaths/min lower</b> <br/> (0.77 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1195<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>18,19,20</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>ED</b> : Emergency department; <b>FEV<sub>1</sub> </b> : Forced expiratory volume in 1 second; <b>ICU</b>: Intensive care unit; IV: Intravenous; MgSO<sub>4</sub>: Magnesium sulfate; <b>OR</b> : Odds ratio; <b>PEF</b>: Peak expiratory flow. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>One study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>) introduced risk of bias, but the rest of the studies were generally well conducted.<br/> <sup>2</sup>I<sup>2</sup> = 28%; P value 0.18; not statistically significant.<br/> <sup>3</sup>Confidence interval includes potential benefit and harm. Very few events and only 1 study (‐2 for imprecision).<br/> <sup>4</sup>Only 1 study (<a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a>) reported this outcome, but no other studies set out to measure it at the outset.<br/> <sup>5</sup>Weighted by sample size.<br/> <sup>6</sup>Two of the 3 studies were at high risk of bias for blinding, and there were some issues with selection bias.<br/> <sup>7</sup>I<sup>2</sup> = 58%; P value 0.07, suggesting statistically significant heterogeneity.<br/> <sup>8</sup>Although only 3 studies reported this outcome, it was not named as an outcome in other studies.<br/> <sup>9</sup>Only 1 study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>), which was assessed as having high risk of bias for several domains.<br/> <sup>10</sup>Only 1 study (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>), which had wide confidence intervals (‐37.02 to 29.02).<br/> <sup>11</sup>Only 1 study reported ED treatment duration, but it was not named as an outcome in other studies.<br/> <sup>12</sup>Only 1 study (<a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a>) had the potential for risk of bias, but all other studies were low risk and included large numbers of participants.<br/> <sup>13</sup>No significant heterogeneity was noted (I<sup>2</sup> = 14%; P value 0.33).<br/> <sup>14</sup>Moderately wide confidence interval (1.75 to 7.06), but after discussion, review authors decided that no downgrade was required.<br/> <sup>15</sup>Two studies (<a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a>; <a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a>) had 'unclear' and 'high' risk of bias, respectively. However, the remaining 6 studies were of low risk and contributed most of the participant numbers.<br/> <sup>16</sup>Some heterogeneity between the studies, which was statistically significant (I² = 50%; P value 0.05). However, when random effects were applied, conclusions were not changed.<br/> <sup>17</sup>Wide confidence intervals (8.64 to 26.17), but does not cross zero.<br/> <sup>18</sup>Very little heterogeneity observed between the studies (I² = 1%), which was not significant (P value 0.39).<br/> <sup>19</sup>Confidence interval (‐0.77 to 0.20) includes significant benefit and potential harm (i.e. crosses the line of no effect).<br/> <sup>20</sup>Only 4 studies reported respiratory rate, but it was not named as an outcome in other studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IV MgSO4 for treating adults with acute asthma in the emergency department</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010909-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of guideline treatment recommendations in acute asthma (adults)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BTS/SIGN</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GINA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NACA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NAEPP</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxygen</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inhaled beta<sub>2</sub>‐agonist</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inhaled antimuscarinic</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sytemic corticosteroids</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV beta<sub>2</sub>‐agonist</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>if nebulised form cannot be used</p> <p>reliably</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> <p>if no response to inhaled form</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV MgSO<sub>4</sub> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> <p>IV or nebulised</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heliox</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV aminophylline/theophylline</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>limited evidence, only after senior consultation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>if inhaled beta<sub>2</sub>‐agonist unavailable </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(✓)</p> <p>as an alternative to IV beta<sub>2</sub>‐agonist </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>x</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>BTS/SIGN: British Thoracic Society and Scottish Intercollegiate Guidelines Network joint guideline; GINA: Global Initiative for Asthma; IV: Intravenous; NACA: National Asthma Council Australia; NAEPP: National Asthma Education and Prevention Program; ✓: Recommended; x: Not recommended; (✓): Recommended with conditions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of guideline treatment recommendations in acute asthma (adults)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010909-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country (centres)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age range (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose (infusion)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐medications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12–85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg/kg (30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV xanthine, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, SB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6–65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 g or 2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>O<sub>2</sub> (if PaO<sub>2</sub> was &lt; 60 mmHg) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thailand (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> if necessary </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scotland (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, nebulised LAMA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA and LAMA, oral corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid (others at physician's discretion), O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA and LAMA, O<sub>2</sub>, IV corticosteroid (discretionary xanthine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (unclear)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, SB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, nebulised LAMA, IV corticosteroid, O<sub>2</sub> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV metaproterenol, IV xanthine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 g (20 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulised SABA, IV corticosteroid, SABA aerosol, IV xanthine</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DB: Double‐blind; IV: Intravenous; LAMA: Long‐acting muscarinic antagonist; O<sub>2</sub>: Oxygen; PaO<sub>2</sub>: Partial pressure of oxygen in arterial blood; PC: Placebo‐controlled; R: Randomised; SABA: Short‐acting beta<sub>2</sub>‐agonist; SB: Single‐blind. </p> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> included adults and children, but only 10 participants were younger than 18 years of age; mean age was 36 (± 13.4) years. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010909-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline severity criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category within trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PEF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Classification*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0001" title="BijaniK , MoghadamniaAA , Islami KhalliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. http://ispub.com/IJAAI/2/1/12115 (accessed 7 March 2013). BijaniKH , MoghadamniaAA , Islami KhaliliE . Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non‐responding to conventional therapy. Acta Medica Iranica2001;39(4):219‐21. ">Bijani 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 after bronchodilator and corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 35 rpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010909-bbs2-0002" title="BilacerogluS , AkpinarM , TirasA , CeliktenE , KalenciD , PerimK . Intravenous magnesium sulphate in acute asthma. American Thoracic Society 97th International Conference; May 18‐23; San Francisco. 2001. ">Bilaceroglu 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PEF increasing &lt; 50% or</p> <p>FEV<sub>1</sub> &lt; 75% predicted after single salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sub>2</sub> = 69 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sub>2</sub> = 64 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010909-bbs2-0003" title="BlochH , SilvermanR , MancherjeN , GrantS , JagminasL , ScharfSM . Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest1995;107(6):1576‐81. ">Bloch 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>FEV<sub>1</sub> &lt; 75% predicted after single salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0004" title="BoonyavorakulC , ThakkinstianA , CharoenpanP . Intravenous magnesium sulfate in acute severe asthma. Respirology2000;5(3):221‐5. ">Boonyavorakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite severity score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 33 rpm</p> <p>HR = 125 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010909-bbs2-0005" title="BradshawTA , MatusiewiczSP , CromptonGK , Alastair InnesJ , GreeningAP . Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma. Respiratory Medicine2008;102(1):143‐9. ">Bradshaw 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>PEF &lt; 75% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% predicted</p> <p>248 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 102 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41% predicted</p> <p>170 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 109 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23% predicted</p> <p>96 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 116 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0006" title="delCastillo RuedaA , Recarte García‐AndradeC , Torres SegoviaFJ . Magnesium, the 4th drug in asthma treatment?. Revista Clinica Espanola1991;189(5):250. ">Del Castillo Rueda 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown (not in analysis)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0007" title="GoodacreS . The 3Mg study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. http://www.controlled‐trials.com/ISRCTN04417063 (accessed 10 March 2014). GoodacreS , CohenJ , BradburnM , GrayA , BengerJ , CoatsT . Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double‐blind, randomised controlled trial. The Lancet Respiratory Medicine2013;1(4):293‐300. GoodacreS , CohenJ , BradburnM , StevensJ , GrayA , BengerJ , CoatsT . The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. Health Technology Assessment2013;18(22):1‐168. ">Goodacre 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One or more of the following: PEF &lt; 50% predicted; RR &gt; 25, HR &gt; 110</p> <p>or cannot complete sentences, but not life threatening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52% predicted</p> <p>433 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0008" title="GreenSM , RothrockSG . Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Annals of Emergency Medicine1992;21(3):260‐5. PughG . Intravenous magnesium for acute asthma. Annals of Emergency Medicine1993;22(3):617. ">Green 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 29 rpm</p> <p>HR = 108 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0009" title="MatusiewiczSP , CusackS , GreeningAP , CromptonGK . A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma [abstract]. European Respiratory Journal1994;7(Suppl 18):14s. ">Matusiewicz 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 250 L/min or &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0010" title="PorterRS , NesterN , BraitmanLE , GearyU , DalseyWC , NesterBA , et al. Intravenous magnesium is ineffective in adult asthma, a randomized trial. European Journal of Emergency Medicine2001;8(1):9‐15. ">Porter 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 100 L/min or &lt; 25% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.5 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR = 31 rpm</p> <p>HR = 110 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0011" title="SilvermanRA , OsbornH , RungeJ , GallagherEJ , ChiangW , FeldmanJ , et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest2002;122(2):489‐97. [0012‐3692] ">Silverman 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 30% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% predicted</p> <p>143 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 102 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0012" title="SinghAK , GaurS , KumarR . A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iranian Journal of Allergy, Asthma, and Immunology2008;7(4):221‐9. SinghAK , GaurSN , KumarR . Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma [Abstract]. European Respiratory Society 18th Annual Congress; Oct 3‐7; Berlin. 2008:[P3620]. ">Singh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 30% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = 127 bpm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0013" title="SkobeloffEM , SpiveyWH , McNamaraRM , GreenspoonL . Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA1989;262(9):1210‐3. ">Skobeloff 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 L/min, not doubled after beta‐agonist, IV corticosteroid, theophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>˜150 L/min (from graph)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR = ˜ 100 bpm from graph</p> <p>RR = ˜ 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010909-bbs2-0014" title="TiffanyBR , BerkWA , ToddIK , WhiteSR . Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest1993;104(3):831‐4. ">Tiffany 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF &lt; 200 L/min, not doubled after albuterol × 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Life threatening</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>bpm: Beats per minute; FEV<sub>1</sub>: Forced expiratory volume in 1 second; HR: Heart rate; PaO<sub>2</sub>: Partial pressure of oxygen in arterial blood; PEF: Peak expiratory flow; rpm: Respirations per minute;RR: Respiration rate.. </p> <p>Classification for the severity subgroup analysis was assigned by an independent clinician and was cross‐checked with study authors' own judgements. Discrepancies were resolved through discussion. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline severity criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/full#CD010909-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010909-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IV MgSO4 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Intensive care unit (ICU) admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 High dependency unit (HDU) admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ED treatment duration (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.33, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Readmission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.66, 7.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Heart rate (bpm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.37 [‐4.13, ‐0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Respiratory rate (breaths/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.77, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Systolic blood pressure (mmHg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐1.89, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [1.75, 7.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 PEF (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [2.14, 7.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.40 [8.64, 26.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Borg Dyspnoea Scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IV MgSO4 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010909-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV MgSO4 versus placebo (subgroup and sensitivity analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hospital admissions (by severity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Life threatening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.46, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admissions (by co‐medications) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nebulised ipratropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No nebulised ipratropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospital admissions (risk of bias sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospital admissions (unpublished sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PEF % predicted (Goodacre change score sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [‐0.55, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PEF L/min (Goodacre change score sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.44 [2.07, 16.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV MgSO4 versus placebo (subgroup and sensitivity analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010909.pub2/references#CD010909-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010909.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010909-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010909-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010909-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010909-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010909-note-0010">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010909\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010909\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010909\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010909\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010909.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010909.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010909.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010909.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010909.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728421121"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010909.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728421124"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010909.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec411ecf19367',t:'MTc0MDcyODQyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 